Cavaliere Carlo, Loperfido Antonella, Ciofalo Andrea, Di Michele Loreta, Begvarfaj Elona, Bellocchi Gianluca, Bugani Marcella, de Vincentiis Marco, Greco Antonio, Millarelli Stefano, Plath Michaela, Sculco Eleonora, Masieri Simonetta
Department of Sense Organs, Sapienza University, 00185 Rome, Italy.
Otolaryngology Unit, San Camillo Forlanini Hospital, 00152 Rome, Italy.
J Clin Med. 2024 Jun 18;13(12):3575. doi: 10.3390/jcm13123575.
: The introduction of biological drugs in the management of chronic rhinosinusitis with nasal polyps (CRSwNP) is allowing new and increasingly promising therapeutic options. This manuscript aims to provide a multicenter trial in a real-life setting on Mepolizumab treatment for severe uncontrolled CRSwNP with or without comorbid asthma. : A retrospective data analysis was jointly conducted at the Otolaryngology-Head and Neck Surgery departments of La Sapienza University and San Camillo Forlanini Hospital in Rome. Both institutions participated by sharing clinical information on patients with CRSwNP treated with Mepolizumab. Patients were evaluated before starting Mepolizumab, at six months and at twelve months from the first drug administration. During follow-up visits, patients underwent endoscopic evaluation, quality of life assessment, nasal symptoms assessment, and blood tests to monitor mainly neutrophils, basophils, eosinophils, and IgG, IgA, and IgE assay. : Twenty patients affected by CRSwNP and treated with Mepolizumab were enrolled (12 females and 8 males with a mean age of 63.7 years). Sixteen patients (80%) had concomitant asthma. During follow-up, a gradual improvement in nasal polyp score, quality of life and nasal symptoms, assessed by SNOT-22 and VAS and loss of smell measured by olfactory VAS, was found. Regarding blood tests, eosinophils decreased gradually, while other blood parameters showed no statistically significant changes. : Mepolizumab has been shown to be effective in the therapeutic management of patients with CRSwNP. Further studies are needed to support our findings and better understand the underlying immune pathways to predict patients' response to biological treatment in CRSwNP.
生物药物引入慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）的治疗中，带来了越来越多有前景的新治疗选择。本手稿旨在提供一项在现实环境中针对伴有或不伴有合并哮喘的严重难治性CRSwNP患者使用美泊利单抗治疗的多中心试验。
罗马的拉齐奥大学耳鼻喉头颈外科和圣卡米洛·福尔拉尼尼医院联合进行了一项回顾性数据分析。两家机构通过共享接受美泊利单抗治疗的CRSwNP患者的临床信息参与研究。在开始使用美泊利单抗之前、首次给药后6个月和12个月对患者进行评估。在随访期间，患者接受内镜评估、生活质量评估、鼻部症状评估以及血液检查，主要监测中性粒细胞、嗜碱性粒细胞、嗜酸性粒细胞以及IgG、IgA和IgE检测。
纳入了20例接受美泊利单抗治疗的CRSwNP患者（12名女性和8名男性，平均年龄63.7岁）。16例患者（80%）伴有哮喘。在随访期间，发现鼻息肉评分、生活质量和鼻部症状（通过SNOT-22和VAS评估）以及嗅觉VAS测量的嗅觉减退情况逐渐改善。关于血液检查，嗜酸性粒细胞逐渐减少，而其他血液参数无统计学显著变化。
美泊利单抗已被证明在CRSwNP患者的治疗管理中有效。需要进一步研究来支持我们的发现，并更好地理解潜在的免疫途径，以预测CRSwNP患者对生物治疗的反应。
